my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
20-12-2011: Pharming Group NV announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent 8,071,532, covering a method of preventing, reducing or treating an ischemia and/or reperfusion injury by administering recombinant C1 inhibitor (Ruconest®/ Rhucin®). The broad claims in the patent provide protection until 2028. This is Pharming's first patent granted on ischemia/reperfusion injury in the U.S., and represents a significant milestone in the continuing development of the Company's C1 inhibitor franchise in additional indications associated with reperfusion injury such as Delayed Graft Function (DGF) and Acute Myocardial Infarction (AMI).
The patent relates to a novel method of using recombinant C1 inhibitor (rhC1 INH), being produced either in cell cultures or in transgenic animals, wherein rhC1 INH is administered after the onset of ischemia or the start of reperfusion. Recombinant C1 inhibitor showed - in contrast to plasma-derived C1 inhibitor - to be still therapeutically active in a time span of 6 hours and therefore particularly useful for unforeseen occurrences of ischemic reperfusion such as stroke and myocardial infarction, whereas other claims are directed to treatment during organ transplantations.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Pharming granted U.S. patent on C1 inhibitor use in ischemia reperfusion injury indications
Pharming Group NV announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent 8,071,532, covering a method of preventing, reducing or treating an ischemia and/or reperfusion injury by administering recombinant C1 inhibitor (Ruconest®/ Rhucin®). ... more
Pharming Group NV announced that it has signed a service agreement with Renova Life, Inc. The agreement covers the development and supply of founder transgenic rabbits from RLI to Pharming. The founder rabbits will enable Pharming to start the commercial production breeding process. The fir ... more
Pharming announces extension of their license agreement for the commercialisation of Ruconest
Biotech company Pharming Group NV announced that they have agreed an extension of their existing agreement with Swedish Orphan Biovitrum to include new territories in the Balkans, North Africa and the Middle East for the commercialization of Ruconest® (recombinant human C1 inhibitor) for th ... more
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombina ... more
PBL awarded two US patents on RNAi
Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,258,285 with fundamental claims directed to compositions to effect gene silencing and US Patent No. 8,263,569 with fundamental claims directed to methods of ind ... more
US Patent Granted for Verona Pharma’s RPL554
Verona Pharma plc announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554. The patent is the fourth patent issued for RPL554 and related compounds in the US.RPL554, Verona Pharma's lead drug candidate, is a dual pho ... more
New Patents Issued to Diffusion Pharmaceuticals
Diffusion Pharmaceuticals LLC announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled “Bipolar Trans Carotenoids Salts and Their Uses” and “Trans Carotenoids, Their Synthesis and Uses,” respectively. These patents include compound, com ... more
U.S. Patent & Trademark Office (USPTO)
The United States Patent and Trademark Office (USPTO) is the Federal agency for granting U.S. patents and registering trademarks. In doing this, the USPTO fulfills the mandate of Article I, Section 8, Clause 8, of the Constitution that the Executive branch "promote the progress of science a ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
